Is Hims' compounded semaglutide the same as Ozempic or Wegovy?

Same active ingredient (semaglutide), same mechanism, similar therapeutic doses. The difference is the manufacturing pathway — branded Ozempic and Wegovy come from Novo Nordisk's commercial production with the full FDA-approved-drug QC pipeline; Hims' compounded version comes from a 503A or 503B compounding pharmacy partner under physician orders. During the FDA-declared semaglutide shortage (which ended in early 2026), compounded semaglutide was widely permitted as a shortage workaround. Post-shortage, FDA scrutiny on compounded GLP-1s has increased significantly, and the long-term availability of compounded-version pricing at this scale is regulatorily uncertain.

Why is Hims compounded semaglutide so much cheaper than Wegovy?

Two factors. (1) Branded Wegovy and Ozempic carry the cost of FDA approval, R&D recovery, marketing, and Novo Nordisk's commercial margins — cash-pay retail runs $1,000–$1,400/month without insurance. (2) Compounded semaglutide is produced at lower per-unit cost by 503A/503B pharmacies operating on telehealth-volume contracts; the active ingredient is the same but the manufacturing-cost structure is different. The $199/mo Hims price reflects this differential, but it's not sustainable indefinitely if FDA further restricts compounding post-shortage — worth being aware of when planning long-term GLP-1 treatment.

What if Hims' compounded semaglutide stops being available?

Real risk worth planning for. FDA officially ended the semaglutide shortage in February 2026 (and tirzepatide earlier), which technically restricts 503A compounding pharmacies' ability to dispense compounded versions of these drugs. Some compounding has continued during the wind-down period, but the long-term availability of $199/mo compounded semaglutide at telehealth scale is uncertain. If you're planning on Hims as your GLP-1 path, ask the prescriber what their continuity plan is if compounded availability shrinks — switching to branded would significantly increase monthly cost.

What about Hims weight-loss customer-service complaints?

The persistent subscription-cancellation-friction complaint pattern that applies to Hims ED and Hims hair-loss applies equally to Hims weight-loss. Customers report cancellation routes that are slow, require multiple contact attempts, or auto-renew before processing completes. The complaints are about billing/customer-service, not about the medication itself. Before subscribing, screenshot the cancellation terms. If you encounter friction, escalation paths are customer service → BBB complaint → card-issuer dispute. The medication delivery and clinical care are separate from the customer-service experience, which is a known weakness at Hims's scale.

Will I gain the weight back if I stop Hims semaglutide?

Most patients regain a significant portion of lost weight when GLP-1s are discontinued without intensive lifestyle support — published data shows roughly two-thirds regained within a year of stopping semaglutide. The biology: GLP-1s reduce appetite and slow gastric emptying; stopping reverses both. This applies regardless of provider — Hims, PeterMD, Marek, or anywhere else dispensing semaglutide. Realistic framing: GLP-1 treatment is typically long-term, similar to managing other chronic metabolic conditions. Some patients transition to lower maintenance doses successfully; few fully stop without regain. Plan for at least 12+ months of continued treatment before evaluating taper options.

ALPHAHEALTH FINDERFind Online Providers

Hims Weight Loss Review

Name: Hims — AHF Editorial Review
Brand: Hims
Rating: 4 (1 reviews)

From $4 · Free consult · 4.2★ on Trustpilot · All 50 States

Get Free Consultation Read our review

Trustpilot

4.2

7,811 verified reviews

7,811+ Verified Reviews

LegitScript Approved

Independently Reviewed

Editorially Rated

AHF Editorial Rating

4.0/5

Compounded semaglutide at one of the lowest entry prices in telehealth — async-light intake fits straightforward GLP-1 candidates.

AHF Editorial Team·Last updated June 10, 2026·Independent review · No vendor-controlled edits

How we rate providers

Services Offered

What Hims treats

Fit Check

Is Hims the right fit for you?

Who it's for

Adults with BMI 30+ (or BMI 27+ with weight-related comorbidity like type 2 diabetes, hypertension, or sleep apnea) who want low-friction access to compounded semaglutide without insurance prior-authorization workflow
Cost-sensitive GLP-1 buyers — Hims compounded semaglutide at $199/mo is meaningfully below most mass-market telehealth weight-loss options and dramatically below cash-pay brand-name Wegovy or Ozempic ($1,000+/mo without insurance)
Existing Hims subscribers across other verticals who want consolidated account management — bundling matters when you're managing ED, hair-loss, and weight-loss subscriptions
Patients comfortable with the regulatory framing of compounded GLP-1s — Hims dispenses compounded semaglutide from 503A/503B partners under physician supervision, but does not offer brand-name Wegovy or Mounjaro at this price point

Who it's not for

Anyone with personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 syndrome — these are FDA-labeled contraindications for GLP-1 medications and Hims' async intake is the wrong environment for that risk-benefit conversation
Patients with severe gastroparesis, prior pancreatitis, or active gallbladder disease — GLP-1s slow gastric emptying and can exacerbate these conditions; a hands-on clinical evaluation is more appropriate
Anyone wanting brand-name Wegovy, Ozempic, or Mounjaro specifically — Hims is compounded-only at this price point. The FDA shortage that historically permitted compounded semaglutide ended in early 2026, so compounded GLP-1 availability is now more restricted than during the peak shortage window
Patients who need integrated metabolic optimization (advanced lipids, fasting insulin, leptin) alongside GLP-1 — Hims' async ED-style intake doesn't include this depth; a clinical hormone-and-metabolic clinic is the better entry

What to expect

Your first 3 months with Hims

01Day 1

Complete the Hims weight-loss intake — weight history, BMI, medical conditions, GLP-1 contraindications (MTC family history, severe gastroparesis, prior pancreatitis), current medications, target weight, and prior weight-loss attempts. Free async consult is the platform default; most prescriptions are written within 24–72 hours.

02Week 1

Lab order issued for baseline metabolic markers — fasting glucose, HbA1c, lipid panel, thyroid (TSH + free T4), liver enzymes, kidney function. Local LabCorp or Quest draw site visit; results in 2–3 business days. Prescriber reviews labs and either confirms protocol or escalates if anything flags.

03Month 1

First compounded semaglutide shipment lands. Standard start is 0.25mg weekly subcutaneous injection — conservative entry to manage GI tolerance. First month typically produces 2–5 pounds of loss alongside appetite reduction. Side effects (nausea, mild GI upset) peak in the first 2–4 weeks then subside for most patients.

04Month 6

Dose titration to therapeutic range (0.5mg → 1mg → 1.7mg → 2.4mg/week depending on response and tolerance). Average loss at 6 months on therapeutic-dose semaglutide runs 10–15% of starting body weight in responders. Follow-up labs at 12 weeks then quarterly. The hard question at 6 months: how to maintain the loss — Hims continues prescribing at maintenance doses, but the regain risk on full discontinuation is the long-term consideration.

Compare

Hims vs the alternatives

vs.

PeterMD

[PeterMD](/online-providers/weight-loss/petermd) and Hims compete on compounded GLP-1 telehealth at similar price points (Hims $199/mo, PeterMD $200–$300/mo depending on dose tier). PeterMD's edge is multi-medication catalog: semaglutide, tirzepatide, and phentermine all available under one prescriber so you can switch medications during treatment if your first protocol underperforms. Hims is semaglutide-focused — if tirzepatide is on your radar, Hims doesn't have it at this price point. AHF rates Hims 4.0 (weight-loss) and PeterMD 4.3 (weight-loss) — gap reflects PeterMD's medication flexibility advantage. Pick Hims if compounded semaglutide at the lowest price is the priority. Pick PeterMD if you want medication-switching flexibility within one provider relationship.

From $62.50·44+ States

4.2

Trustpilot Rating

Starting Price

All 50 States

State Coverage

2-5 Days

Turnaround

Honest Breakdown

What Works Well

Extremely affordable ED meds starting at $4/dose
Massive scale with 2.5M+ active subscribers
Free online consultations included
Publicly traded company (NYSE: HIMS) - established trust
Available in all 50 states
Wide range of treatments in one platform
Discreet packaging and fast shipping
Chewable ED options (Hard Mints) available

Watch Points

Subscription cancellation can be difficult
Mixed customer service reviews
No injectable TRT yet (coming 2026)
Uses compounded GLP-1 (not brand-name Ozempic/Wegovy)

See if Hims is right for you — Free Consultation

Real Questions

What people actually ask about Hims

Yes — Hims operates as a publicly-traded U.S. telehealth platform with licensed physicians prescribing in each state served. Compounded semaglutide is dispensed through 503A/503B compounding pharmacy partners under physician orders. The medication is real, the prescribing process is real, and the legitimacy infrastructure (NYSE: HIMS, $2.35B revenue, public company financial disclosures) is verifiable. The watch points are platform-scale issues (async-rigor at volume, cancellation friction) and the regulatory-shifting landscape for compounded GLP-1s post-FDA-shortage-end, not the legitimacy of the basic operation.

Ready to start with Hims?

Free consultation. Independently reviewed. Board-certified physicians.

Get Free Consultation

Secure telemedicine · HIPAA compliant · Cancel anytime

4.2★From $4 · All 50 States

Start with Hims